Athersys, Inc. - Financial and Strategic Analysis Review Summary Athersys Inc (Athersys) is a clinical stage biopharmaceutical company engaged in developing highly differentiated, potential best in class therapeutics designed to treat significant and life-threatening diseases. The Company's lead programs are in the areas of obesity, cardiovascular disease, and bone marrow transplant support. In July 2007, the company initiated a Phase I clinical trial for the lead product candidate ATHX-105, a novel treatment for obesity in the United Kingdom and completed this trial in 2008. This report presents an in-depth business, strategic and financial analysis of Athersys, Inc.. The report provides a comprehensive insight into the company, including business structure and operations, executive biographies and key competitors. The hallmark of the report is the detailed strategic analysis and views on the company. Scope -The company's strengths and weaknesses and areas of development or decline are analyzed. Financial, strategic and operational factors are considered. -The opportunities open to the company are considered and its growth potential assessed. Competitive or technological threats are highlighted. -The report contains critical company information - business structure and operations, the company history, major products and services, key competitors, key employees and executive biographies, different locations and important subsidiaries. -It provides detailed financial ratios for the past five years as well as interim ratios for the last four quarters. -Financial ratios include profitability, margins and returns, liquidity and leverage, financial position and efficiency ratios. Reasons to buy -A quick "one-stop-shop" to understand the company. -Enhance business/sales activities by understanding customers' businesses better. -Get detailed information and financial & strategic analysis on companies operating in your industry. -Identify prospective partners and suppliers - with key data on their businesses and locations. -Capitalize on competitors' weaknesses and target the market opportunities available to them. -Compare your company's financial trends with those of your peers / competitors. -Scout for potential acquisition targets, with detailed insight into the companies' strategic, financial and operational performance. http://www.companiesandmarkets.com/link.asp?id=O31VJHXX673765 CONTACT: Mike King, Director, www.companiesandmarkets.com Tel: +44 7813 784 393 Fax: +44 1536 790 144 e-mail: info@companiesandmarkets.com WWW: http://www.companiesandmarkets.com/link.asp?id=O31VJHXX673765 M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com. For full details for ATHX click here.
![]()
Email Print Archives Feedback Email Article Link
Close X
Most Popular News
UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday December 3 12:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.
The TradingMarkets Directory
Stocks
Options
Forex
E-mini/Futures
How to Trade
Tools
PowerRatings
Blogs
|